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can be optimized by boosting the primary dose by endocavitary brachytherapy (EBT).
METHODS AND MATERIALS: To study the role of EBT, three data sets on NPC, that is, the
‘‘Vienna’’, ‘‘Rotterdam,’’ and ‘‘Amsterdam’’ series, with a total number of 411 advanced NPC
patients, were available. The Rotterdam series consisted of 72 patients (34 T1,2Nþ and 38
T3,4N0,þ) and were treated with neoadjuvant chemotherapy followed by external beam radiotherapy
(dose 70/2 Gy). After 70/2 Gy, a boost was applied by EBT (in case of T1,2Nþ) or stereotactic radi-
ation (in case of T3,4 tumors). The Amsterdam (Antoni van Leeuwenhoek Hospital/The Netherlands
Cancer Institute) series consisted of 76 patients (40 T1,2Nþ and 36 T3,4N0,þ) and were irradiated to
a dose of 70/2 Gy with concomitant chemotherapy. No second boost by EBT was applied.
RESULTS: In the case of T1,2Nþ tumors, the local relapse rate (LRR) was significantly smaller if
a boost was applied, that is, 0% (0/34, EBT boost) vs. 14% (14/102, no EBT boost) ( p5 0.023).
For the T3,4 tumors, an LRR of 10% (4/38, EBT or stereotactic radiation boost) vs. 15% (17/111,
no boost) was found ( p5 0.463).
CONCLUSIONS: In the case of advanced NPC (T1,2Nþ vs. T3,4Nþ,0), for early T-stages
(T1,2Nþ), an EBT boost seems an excellent way to deliver highly conformal high doses of radia-
tion to the nasopharynx, with high local control rates. For advanced T-stages (T3,4Nþ,0), the reduc-
tion in LRR (10% vs. 15%) was not significant ( p5 0.463).  2013 American Brachytherapy
Society. Published by Elsevier Inc. All rights reserved.Keywords: Head and neck cancer; Nasopharynx; Boost irradiation; Brachytherapy; Endocavitary; Prognostic factorIntroduction
Nasopharyngeal cancer (NPC) is highly prevalent in
provinces of Southern China (e.g., Hong Kong), with an in-
cidence rate of up to 20 per 100,000 inhabitants (1). In
contrast, it is a relatively rare disease entity in the
Netherlands, with an incidence of close to 1 per 100,000.mber 2011; received in revised form 15 March 2012;
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.1016/j.brachy.2012.06.001Some of the countries of the Mediterranean Basin report
an incidence rate in between 1 and 5 per 100,000 (2). The
nasopharynx is a midline-located cuboidal-shaped cavity,
anatomically located posteriorly to the nasal cavity and
cranial posteriorly bordered by the base of skull. It is heavily
infested with lymphoid tissue and surrounded by a network
of critical structures. Laterally, a close anatomic relationship
exists with the parapharyngeal space, containing critical
structures such as the cranial nerves IXeXII. By traversing
the foramen lacerum, the nasopharynx interconnects directly
or by lymphatics with the middle cranial fossa. Consequen-
tially, this anatomic route can cause NPC cells to destruct
critical structures of the parasellar region, such as the cranial
nerves IeVIII, inner ear, and carotid arteries. Approximately
80% of patients develop lymphadenopathy and/or havehed by Elsevier Inc. All rights reserved.
85P.C. Levendag et al. / Brachytherapy 12 (2013) 84e89lymph nodes at the time of initial diagnosis (3), with
frequently a typical involvement of the lymphnodes in Level
V. Moreover, staging of NPC reveals that most patients have
advanced disease, that is, either T1,2Nþ or T3,4N0,þ, Stage
III/IV disease. Frequently, however, nodal disease in NPC
can be cured by a combination of chemotherapy (CHT)
and radiation therapy (RT) (mostly given in a ‘‘concomitant’’
fashion currently). One of the single most important prog-
nostic factors is the extent of the primary lesion at the time
of clinical presentation (4, 5). The purpose of the present
report is to analyze whether, when using the Rotterdam
nasopharyngeal applicator (RNA; see also Fig. 1), a boost
of 11 Gy by endocavitary brachytherapy (EBT) is of signif-
icance in obtaining high local control rates in advanced
(T1,2Nþ) NPC (6).Methods and materials
Advanced NPC can be subdivided into T1,2Nþ and
T3,4N0,þ patients. Three databases of advanced NPC
patients (‘‘Vienna’’, ‘‘Rotterdam’’, and ‘‘Amsterdam’’
series) have been analyzed to investigate whether local
tumor control in NPC can be increased with the application
of a highly focused, second boost dose of radiation. The
radiation was applied either by EBT (in case of T1,2
tumors) or stereotactic radiation (in case of T3,4 tumors)
(7, 8). With regard to the Vienna (67 T1,2Nþ and 65
T3,4N0,þ), Rotterdam (34 T1,2Nþ and 38 T3,4N0,þ),
and Amsterdam series (40 T1,2Nþ and 36 T3,4N0,þ),
the RT guidelines for the techniques to be used were quite
similar for the first part of the treatment, that is, 46/2 Gy by
external beam RT to the primary tumor site and bilateral
neck, to be followed by a booster dose of 24/2 Gy to the
primary tumor and lymphnodal disease. The gross tumorFig. 1. (a) ‘‘Old’’ type Rotterdam nasopharyngeal applicator (RNA) and
(b) ‘‘new’’ type RNA. Over time, the RNA was slightly modified. Flanges
of both catheters were tilted more sideways; thus, the dose will be
‘‘pushed’’ more laterally toward/in parapharyngeal space.volume of the primary tumor was delineated with the use
of magnetic resonance imaging (matching). Patients were
treated in supine position with a head fixation mask. Dose
is prescribed according to the International Commission on
Radiation Units and Measurements guidelines.
All advanced NPC patients received CHT. The ‘‘Vienna
protocol’’ patients were treated by neoadjuvant and concom-
itant combined CHT, the ‘‘Rotterdam protocol’’ patients by
neoadjuvant CHT, and the ‘‘Amsterdam protocol’’ by
concomitant CHT. To deliver the fractionated EBT boost
dose of 11 Gy on an outpatient basis, an institutionally de-
signed and currently commercially available, silicone after-
loading device (RNA; Fig. 1) was used in the Vienna and
Rotterdam protocols. For applying EBT, RNA was con-
nected to a microSelectron high dose rate (HDR),
a remote-controlled afterloading device containing an 192Ir
point source (37 MBq). No second boost was given in the
Amsterdam series.Results
Local control
Table 1 denotes a summary for the ‘‘Rotterdam,’’ ‘‘Amster-
dam,’’ and the ‘‘Vienna’’ series, stratified for the T1,2Nþ
and T3,4N0,þ cancers (advanced NPC), number of patients,
number of local relapses (LRs), and percentage of patients
developing distantmetastasis (Mþ). For the ease of interpreting
the data, a letter code was assigned to the different treatment
protocol groups (see Table 1). For T1,2Nþ tumors, no LRs
(0%; 0/34) were found for Group B (Rotterdam series), in
contrast to Group C (Amsterdam series) (10%; 4/40)
(p5 0.058). In the T3,4N0,þ category, brachytherapy (BT)
does not impact the LR rate (LRR), that is, an LRR of 11%
(4/38) for Group B vs. 11% (4/36) for Group C (p5 0.935).
With respect to the Vienna protocol series, an LRR for
T1,2Nþ tumors of 12% (8/67) for Groups Cþ B (i.e., plus
EBT boost) vs. 16% (10/62) for Groups C B (i.e., no EBT
boost) was observed (p5 0.492). Same was true for the ad-
vanced T-stage categories (T3,4Nþ,0): An LR of 26% (17/
65) vs. 19% (13/69) for theGroups (CþB) vs. (C B), respec-
tively, was seen. Finally, because therewas an overlap and simi-
larity for the Groups C and (C B), we compared the LRR of
the group of patients denoted as Ctotal (5Cþ [C B]) for
T1,2Nþ and T3,4N0,þ cases. For Group Ctotal T1,2Nþ
cancers, an LR of 14% (14/102) vs. 0% (0/34) was observed
for the Group B ( p5 0.023). For Group Ctotal T3,4N0,þ
tumors, an LR of 15% (17/111) vs. 11% (4/38) for the Group
B was seen (p5 0.463). The regional relapse rate for small
tumors was 0%, for advanced tumors depending on the tumor
stage variable from 7% (T1,2Nþ, T3,4N0,þ, and Rotterdam
series) to 15% (T1,2Nþ, T3,4N0,þ, and Vienna series without
boost) and 16% (T1,2Nþ, T3,4N0,þ, and ViennaþBoost).
Seventeen of 72 N0,1,2,3 (24%) patients, treated by the
Rotterdam protocol, developed Mþ at some point in time;
Table 1
Protocol treatment modalities per institute
Treatment protocol per institute/trial design Group NPC stages Number Local relapse (%) Metastasis
70 Gy EBRTþBT boost (Rotterdam series) T1,2N0 8 1 (13) 0
70 Gy EBRT (Amsterdam series) T1,2N0 11 1 (9)
Neoadjuvant CHTþ 70 Gy EBRTþBT boost (Rotterdam series) B T1,2Nþ 34 0 (0) 8 (24)
T3,4N0,þ 38 4 (11) 9 (24)
70 Gy EBRTþ cCHT (Amsterdam series) C T1,2N0 2 0 (0)
T1,2Nþ 40 4 (10) 12 (30)
T3,4N0,þ 36 4 (11) 6 (17)
70 Gy EBRTþ cCHT with BT boost (Vienna trial) CþB T1,2Nþ 67 8 (12) 18 (27)
T3,4N0,þ 65 17 (26) 16 (25)
70 Gy EBRTþ cCHT without BT boost (Vienna trial) CB T1,2Nþ 62 10 (16) 18 (29)
T3,4N0,þ 69 13 (19) 8 (12)
70 Gy EBRTþ cCHT (Cþ (CB)) Ctotal T1,2Nþ 102 14 (14) 30 (29)
T3,4N0,þ 111 17 (15) 14 (13)
NPC5 nasopharyngeal cancer; EBRT5 external beam radiotherapy; BT5 brachytheraphy; CHT5 chemotherapy; cCHT5 concomitant chemotherapy;
C5Chemotherapy; Rotterdam, Amsterdam, and Vienna trials5 treatment protocols per institute, for explanation see text; Letter codes: B, C, CþB, C B,
and Ctotal5 treatment protocols per institute, for explanation see text.
Local relapse rate and number of distant metastasis.
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24%, 26%, and 20%, respectively. A higher number of
patients with Mþ was observed with higher N-stage at
presentations, that is, N0, N1, N2, and N3 disease corre-
sponded with 0/17 (0%), 3/16 (19%), 10/33 (30%), and
5/14 (36), respectively, of patients having Mþ disease.Discussion
General introduction
Over the years, across countries, the principles of how to
treat NPC have become more or less standardized, albeit
that in practice, for example, different fractionation sched-
ules and RT techniques are in use. The Rotterdam and Am-
sterdam protocols focus on conventional fractionation
schedules with total doses up to 70/2 Gy. It has long been
established that NPC is a ‘‘chemoradioresponsive’’ tumor,
and at the present time, many of the reported series are
therefore basically the outcome of RT and (concomitant)
CHT. This article evaluated the 8-year results of a series
of patients treated in the Erasmus MC-Daniel den HoedTable 2








Shen et al. (5) 154 61 78/1.2e1.5 2
Chen et al. (9) 64 31 64.4e68.9/1.8 SRT 12e15/3
Teo et al. (10) 2426 52 66/2 BT 10e18e2
SRT/3D 15
Kwong et al. (11) 50 25 76/2.17 SMART (see
Lu et al. (12) 33 29 66/2 BT 10/5
Jian et al. (13) 48 57 74.4/1.2 2 See EBRT
Levendag et al. (6) 91 48 60/2 BT 18/3
70/2 SRT 12/3
3D5 three dimensional; NPC5 nasopharyngeal cancer; FU5 followup; E
accelerated radiation therapy; SRT5 stereotactic radiotherapy; BT5 brachyther
tive/fraction size.Cancer Center (Rotterdam) and those treated in Amsterdam
series. Given the intrinsic differences between the two
protocols and consistency of execution of each of the proto-
cols over many years, the question was raised whether
a booster dose of radiation to the primary tumor site after
70/2 Gy in conjunction with neoadjuvant CHT (Rotterdam
protocol) is of clinical value as opposed to the treatment
regime of 70/2 Gy with concomitant CHT (Amsterdam
protocol) and no EBT boost.Local control early disease
A number of classical articles on NPC suggest a dosee
effect relationship for the primary tumor. Table 2 summa-
rizes some of the frequently cited articles on local tumor
control. The reported results concur with our findings: An
EBT boost benefits particularly patients with NPC with
early T-stage, that is, T1,2Nþ tumors. For example, Teo
et al. (10) showed a significant doseetumor control rela-
tionship at doses above the conventional tumoricidal dose
levels for T1 and T2a tumor stages; their report justifies





93 (72% stage III/IV) 3 yr 85 (72% stage III/IV)
1/5e6e8 vs.
/5
LF HR 0.33 (T1eT2a); p5 0.01
EBRT) 96 (T3þ T4) 2 yr 92 (T3þ T4) 2 yr
94 (T1þ T2) 2 yr 82 (T1þ T2)
93 (T3þ T4) 3 yr 72 (T3þ T4) 3 yr
100 (T1þ T2) 2 yr 61 (T1þ T2) 2 yr
86 (T1þ T2) 2 yr 66 (T1þ T2) 2 yr
BRT5 external beam radiotherapy; SMART5 simultaneous modulated
apy; LF5 local failure; HR5 hazard ratio; Gy cum/fr. size5Gy cumula-
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tant as patients with an LR have an increased risk of Mþ;
more so, although reirradiation in case of a relapse can be
very helpful and therefore justified, it can also be associated
with a high risk of complications. Wang (14) routinely
included BT as a boost dose in the primary treatment:
T1,2 tumors had a 5-year LR-free survival of 91% (with
BT) vs. 60% (without BT). Chang et al. (15) demonstrated
that BT had a significant impact on local control in early-
stage NPC. Levendag et al. (16) showed that a local control
rate of 97% at 3 years can be reached with few complica-
tions using an EBT boost after a previous dose of
60e70 Gy. Leung et al. (17) showed that dose escalation
beyond 66 Gy significantly improved the 5-year actuarial
LR-free survival. In summary, some evidence in the litera-
ture, although being non-Class I evidence derived from
nonrandomized data, points toward a beneficial effect, that
is, a lower LRR with high doses of radiation in early-stage
disease. In our article, in early-stage disease (Table 2,
T1,2N0 NPC, data derived from the Rotterdam and Amster-
dam series), only one LR was found in the small cohort of
the Rotterdam series (n5 8; using EBT boost) and one LR
in the Amsterdam series (n5 11; no EBT boost). That is,
no significant difference between both institutions was
established.
Local control in advanced disease
The prime purpose of this article was to analyze in some
detail the overall local control rate in advanced staged
disease (T1,2Nþ and T3-4N0,þ NPC) when randomized
for a so-called second boost type technique by EBT. Most
NPC patients present with advanced-stage disease: When
comparing 34 T1,2Nþ patients of the Rotterdam series
with the 40 T1,2Nþ patients of the Amsterdam series, no
significant differences between the LRR in both institu-
tions, that is, 0/40 (0%) vs. 4/40 (10%), respectively, could
be observed ( p5 0.058). Similar findings were found for
T3,4N0,þ group of patients: 4/38 (11%; Rotterdsam series)
vs. 4/36 (11%; Amsterdam series), respectively.Table 3
Definition/delineation table for patient points on CT
Patient point on CT Structure Dosis constraints Exp
Pt-Ri Pterygoid right 80% Lin
o
Pt-Le Pterygoid left 80% Lin
o
R Node of Rouviere 130% Mid
BOS Base of skull 100% Mid
Pal-Ri Soft palate right 100% Tra
Pal-Le Soft palate left 100% Tra
C-Ri Cochlea right Mean!35/2 Gy
C-Le Cochlea left Mean!35/2 Gy
BS Brainstem Maximum!54/2 Gy
Cord Cord Maximum!50/2 Gy
CT5 computed tomography; Pt-Ri5 pterygoid plates right side; Le5 left sid
palate on the right side.With the current therapy, the local failure rate in early
NPC disease (T1,2N0) is low (2/19; 11%). The third data-
base, the Vienna protocol, designed by the International
Atomic Energy Agency located in Vienna, consisted of 263
patients. The selected institutions for the Vienna trial treated
advanced NPC by external beam radiotherapy to a dose of
70/2 Gy, using techniques similar as in the Amsterdam and
Rotterdam series. However, CHT was applied according to
protocol using neoadjuvant CHT and weekly concomitant
CHT. For illustrative purposes, the Vienna protocol was also
studied in conjunction with the outcome data of the
Rotterdam/Amsterdam series. Summating all cases treated
with a boost (Cþ [Cþ B]5Ctotal), and comparing them
with all patients without an EBT boost, now reveals a signif-
icant difference in the LRR (Table 2) for advanced stage.
This, however, was only the case for the T1,2Nþ tumors:
EBT boost 0% (0/34; Group B) vs. no EBT boost 14%
(14/102; Group (Cþ [C B]) ( p5 0.023). For T3,4 tumors,
most likely because of inadequate tumor coverage by virtue
of the RNA design, EBT does not significantly decreases
the LRR: The difference of 11% (4/38; Group B) vs. 15%
(17/111; Group Cþ (C B)) vs. was found to be nonsignif-
icant ( p5 0.463).
Regional and distant metastases
The regional relapse rate for small tumors was 0%, for
advanced tumors depending on the tumor stage varied from
7% to 16%. An article by Kwong et al. (18) reports the LR
to be an independent prognostic indicator for the develop-
ment of Mþ. Mþ was also shown to correlate with the
Nþ status of the neck. In a recent issue (2009) of the
Chinese Journal of Cancer, an article by Han et al. (19)
showed by multivariate analysis that T-classification had
no predictive value for local control and survival, whereas
N-classification was a significant prognostic factor for over-
all ( p!0.001), metastasis-free ( p!0.001), and disease-
free survival ( p5 0.003). In summary, in their series of
305 NPC patients, N-classification was the main factor
for prognosis. Moreover, a higher number of patients withlanation
e between the right styloid process and pterygoid plates on the right side;
n this line, the Pt point is located at one-third of the styloid process.
e between the left styloid process and pterygoid plates on the left side;
n this line, the Pt point is located at one-third of the styloid process.
line point, anterior of C1
line point anterior of the clivus
nsition of palatum molle to palatum durum
nsition of palatum molle to palatum durum
e; R5Rouviere; BOS5 base of skull; Pal-Ri5 boundary soft palate/hard
Fig. 2. Dose summation for a nasopharyngeal cancer (NPC) case treated with external beam radiotherapy and endocavitary brachytherapy. Three-
dimensional dose summation is mandatory for accurate dose distribution calculations. The figure displays an example of such summated dose distribution
of an NPC case. Dose trajectories were 46/2 Gy (intensity-modulated radiation therapy [IMRT]) neck and primary tumor, 24/2 Gy (IMRT) primary tumor
(first boost), and 11 Gy (second boost) by means of fractionated brachytherapy.
88 P.C. Levendag et al. / Brachytherapy 12 (2013) 84e89Mþ was observed with higher N-stage, that is, N0, N1, N2,
and N3 disease corresponded with 0%, 19%, 30%, and
36%, respectively, of patients having Mþ disease.Conclusion
In the present study, for the T1,2Nþ patients, less LRs
were found for those patients treated with an EBT boost
( p5 0.023); this corroborates with literature findings (20).
In fact, with regard to T3,4N0,þ NPC, the reduction of
the LRR was found to be nonsignificant ( p5 0.463). These
observations are in line with what is to be expected of EBT
using the RNA: Albeit a very useful tool, it was originally
designed for small primary lesions (T1,2) only. Moreover,
some factors might be of additional advantage in future
treatment of advanced NPC cases. (1) Stereotactic radiation
is considered a valuable treatment option, in particular for
the advanced cases. (2) The RNA is recently modified, that
is, slightly redefined by tilting the flanges of the applicator
somewhat more laterally (Fig. 1). This way, it is found to
be easier to push the dose laterally into the parapharyngeal
space to an adequate dose level. (3) The dose can be
prescribed more accurately. The tumor tissue (TT) and
normal tissue patient (dose) points were formerly depicted
on two orthogonal X-ray films (as described in detail in
previous publications from our group); instead, they are
now transferred routinely into computed tomography
images instead (Table 3). The dose is prescribed to the en-
compassing isodose, incorporating all tumor-related dose
points, that is, the so-called ‘‘BOS’’ (base of skull) point,
‘‘R’’ (Rouviere) point, ‘‘Pal’’ right/left points, and the twonewly defined patient points, that is, the ‘‘Pt’’ points (ptery-
goid plates) and ‘‘St’’ (styloid process) points. (4) To reach
high doses in the TT points, small volumes (0.02 cm3) are
assigned to the dose points. Thus, when using the inverse
planning simulated annealing (automated inverse planning),
this could further increase the dose in the TT points. (5).
Three-dimensional dose summation of intensity-modulated
radiation therapy and BT is still experimental and currently
not routinely available in our clinic as yet (Fig. 2), but it has
great potential in future cases of head and neck cancer, asso-
ciated with (extreme) high doses being applied in TTs (and
normal tissues).
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